Related Experiment Video
Updated: May 15, 2025

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
Dynamic DNA-Based Nanoadjuvants for TLR9 Clustering and Innate Immune Activation in Dendritic Cells
Zhaoyue Lv1,2, Xiaocui Guo2,3, Rui Zhang1
1Department of Chemistry, State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, College of Chemistry and Materials, Fudan University, Shanghai 200438, P.R. China.
Abstract:
The regulation of toll-like receptor (TLR) clustering is a pivotal strategy for enhancing innate immune responses, but the development of methods to precisely control receptor assembly remains challenging. Herein, we present a dynamic, DNA-based nanoadjuvant that triggers TLR9 clustering for potent innate immune activation in dendritic cells (DCs) via in situ assembly in lysosomes. This nanoadjuvant integrates CpG oligonucleotides (TLR9 ligands) and cytosine-rich DNA sequences (acid-responsive sequences) into a polymeric nanoframework via a cascade hybridization chain reaction. Upon lysosomal internalization, the nanoadjuvants form large-sized aggregates through cytosine protonation-induced i-motif formation, a process driven by the acidic lysosomal environment. This assembly consumes lysosomal protons, thus reducing lysosomal acidity and attenuating hydrolase activity, leading to enhanced intralysosomal retention of nanoadjuvants. Moreover, the nanoadjuvant aggregates promote CpG ODN contact with the lysosomal membrane, thereby facilitating prolonged ligand-receptor interactions and efficient TLR9 clustering. Consequently, the nanoadjuvant aggregates induce efficient DC maturation, secretion of cytokines, and T-cell proliferation, culminating in robust antitumor immunity both in vitro and in vivo. Our approach offers a novel strategy to manipulate receptor assembly using an environmentally stimulus-responsive system, holding significant promise for vaccine adjuvants and cancer immunotherapy.

